<DOC>
	<DOCNO>NCT01872078</DOCNO>
	<brief_summary>To assess effect AZD4901 give multiple dos female Polycystic Ovary Syndrome</brief_summary>
	<brief_title>A Study AZD4901 Females With Polycystic Ovary Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Endocrine System Diseases</mesh_term>
	<criteria>Female patient age 18 45 year ( inclusive ) . Suitable vein cannulation repeat venipuncture . Body mass index ( BMI ) 18 40 kg/m2 ( inclusive ) . A diagnosis polycystic ovary disease . Amenorrhea oligomenorrhea ( define ≤ 6 menses per year ) . Negative serum pregnancy test screening . Negative urine pregnancy test randomisation . Not breastfeed . Not pregnant within 6 month prior screen . Perimenopausal reach natural menopause , define FSH &gt; 10 IU/L . Menstruated within month prior baseline visit . Hysterectomy bilateral oophorectomy . Clinically relevant disease abnormality ( past present ) , particular cause abnormal vaginal bleeding . Withdrawals oral contraceptive LH level 3 IU/L retested within 7 ± 1 day baseline visit .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Pharmacokinetics , Pharmacodynamics , endocrinopathies , PCOS , female , hormone , LH</keyword>
</DOC>